Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.195
-0.005 (-0.42%)
Sep 28, 2026, 11:50 AM EDT - Market open
Actinium Pharmaceuticals Revenue
Actinium Pharmaceuticals had revenue of $35.00M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $35.09M. In the year 2025, Actinium Pharmaceuticals had annual revenue of $90.00K.
Revenue (ttm)
$35.09M
Revenue Growth
n/a
P/S Ratio
1.08
Revenue / Employee
$1,299,630
Employees
27
Market Cap
37.57M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 90.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 81.00K | -949.00K | -92.14% |
| Dec 31, 2022 | 1.03M | -114.00K | -9.97% |
| Dec 31, 2021 | 1.14M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.62M |
| Aligos Therapeutics | 31.52M |
| Celularity | 26.55M |
| Veru Inc. | 16.89M |
| Immutep | 13.79M |
| Metagenomi Therapeutics | 13.56M |
| Seres Therapeutics | 1.88M |
| CervoMed | 331.30K |
ATNM News
- 23 days ago - Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PRNewsWire
- 26 days ago - Actinium Pharmaceuticals Slides: Investor presentation - Filings
- 6 weeks ago - Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update - PRNewsWire
- 7 weeks ago - Actinium Pharmaceuticals Slides: Investor presentation - Filings
- 7 weeks ago - Actinium Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 3 months ago - Actinium Pharmaceuticals Slides: Investor presentation - Filings
- 3 months ago - Actinium presented preclinical data on ATNM-400 in NSCLC at SNMMI 2026 - TheFly
- 3 months ago - Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer - PRNewsWire